Hepatocellular Cancer

P2, N=60, Active, not recruiting, Intra-IMMUSG Pte Ltd

P2, N=3, Terminated, Emory University | N=19 --> 3 | Trial completion date: Nov 2026 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> May 2025; Slow Accrual

P2, N=40, Recruiting, Fudan University | Not yet recruiting --> Recruiting

P1, N=41, Not yet recruiting, Shanghai Henlius Biotech

P=N/A, N=150, Recruiting, Fudan University | Not yet recruiting --> Recruiting

P2, N=350, Recruiting, Fudan University | Not yet recruiting --> Recruiting

FIRRM was identified as a novel driver gene in HCC, which accelerated tumor proliferation through PLK1-mediated mitotic progression and promotion of the G2/M transition. These findings suggest that FIRRM is a promising target for HCC therapy.

Accurate diagnoses and appropriate therapeutic strategies are essential for patients presenting with multiple liver tumors showing heterogeneous imaging features and elevated CA19-9 levels.

Its protective antioxidant effects in normal cells and anticancer effect make it a promising candidate for preventing the progression of HCC. The online version contains supplementary material available at 10.1007/s10616-026-00963-3.

Serum miR-182-5p and miR-127-5p levels as predictive biomarkers for MASLD were evaluated using receiver operating characteristic (ROC) analysis. miR-182-5p and miR-127-5p could serve as novel biomarkers for MASLD diagnosis and may offer a novel approach for the disease's therapy.

These anti-CD44E CAR T cells exhibited specific cytotoxicity against CD44-positive HCC cells in both in vitro and in vivo models and importantly, did not induce detectable toxicity in vital organs in animal models. Our findings suggested that CD44E-targeting CAR T cell therapy might represent a promising therapeutic approach for HCC treatment.

ROC analysis revealed that the selected miRNAs, along with their related biomarkers, have enhanced the overall sensitivity and specificity (88% and 0.6%) of the GIII group compared to the GI group. The selected panel of miRNAs has served as diagnostic biomarkers against HCV-HCC.